Antimalarial drugs will be essential tools at all stages of malaria elimination along the path towards eradication, including the early control or “attack” phase to drive down transmission and the later stages of maintaining interruption of transmission, preventing reintroduction of malaria, and eliminating the last residual foci of infection. Drugs will continue to be used to treat acute malaria illness and prevent complications in vulnerable groups, but better drugs are needed for elimination-specific indications such as mass treatment, curing asymptomatic infections, curing relapsing liver stages, and preventing transmission. The ideal malaria eradication drug is a coformulated drug combination suitable for mass administration that can be administered in a single encounter at infrequent intervals and that results in radical cure of all life cycle stages of all five malaria species infecting humans. Short of this optimal goal, highly desirable drugs might have limitations such as targeting only one or two parasite species, the priorities being Plasmodium falciparum and Plasmodium vivax. The malaria research agenda for eradication should include research aimed at developing such drugs and research to develop situation-specific strategies for using both current and future drugs to interrupt malaria transmission.
Vyšlo v časopise: A Research Agenda for Malaria Eradication: Drugs. PLoS Med 8(1): e32767. doi:10.1371/journal.pmed.1000402 Kategorie: Review prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000402
1. ChandaP
HamainzaB
MulengaS
ChalweV
MsiskaC
2009 Early results of integrated malaria control and implications for the management of fever in under-five children at a peripheral health facility: A case study of Chongwe rural health centre in Zambia. Malar J 8 49
2. 2007 United Arab Emirates certified malaria-free. Wkly Epidemiol Rec 82 30 32
3. PloweCV
2009 The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg 103 S11 S14
4. TakalaSL
PloweCV
2009 Genetic diversity and malaria vaccine design, testing and efficacy: Preventing and overcoming ‘vaccine resistant malaria’. Parasite Immunol 31 560 573
5. Kelly-HopeL
RansonH
HemingwayJ
2008 Lessons from the past: managing insecticide resistance in malaria control and eradication programmes. Lancet Infect Dis 8 387 389
6. PloweCV
AlonsoP
HoffmanSL
2009 The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis 200 1646 1649
7. The Roll Back Malaria Partnership 2010 The global malaria action plan for a malaria-free world. Geneva The Roll Back Malaria Partnership
8. PriceRN
TjitraE
GuerraCA
YeungS
WhiteNJ
2007 Vivax malaria: Neglected and not benign. Am J Trop Med Hyg 77 79 87
9. MarshK
1992 Malaria–a neglected disease? Parasitology 104 S53 S69
10. SongJ
SocheatD
TanB
DaraP
DengC
2010 Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J 9 57
11. AlkerAP
LimP
SemR
ShahNK
YiP
2007 Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 76 641 647
12. DondorpAM
NostenF
DasD
PhyoAP
2009 Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361 455 467
13. NyuntMM
2007 Pharmacologic advances in the global control and treatment of malaria: Combination therapy and resistance. Clin Pharmacol Ther 82 601 605
14. BoniMF
SmithDL
LaxminarayanR
2008 Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A 105 14216 14221
15. PriceRN
DorseyG
AshleyEA
BarnesKI
BairdJK
2007 World Antimalarial Resistance Network (WARN) I: Clinical efficacy of antimalarial therapy. Malar J 6 119
16. Cox-SinghJ
DavisTM
LeeKS
ShamsulSS
MatusopA
2008 Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 46 165 171
17. NajeraJA
2001 Malaria control: Achievements, problems and strategies. Parassitologia 43 1 89
18. FeachemRGA
2010 Shrinking the malaria map: A guide on malaria elimination for policy makers. Chapter 6. San Francisco The Global Health Group, UCSF Global Health Sciences
19. SnowdenFM
2005 The conquest of malaria. Italy 1900-1962. New Haven Yale University Press
20. Bruce-ChwattLJ
1959 Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. Bull World Health Organ 21 737 772
21. KanekoA
TaleoG
KalkoaM
YamarS
KobayakawaT
2000 Malaria eradication on islands. Lancet 356 1560 1564
22. von SeidleinL
GreenwoodBM
2003 Mass administrations of antimalarial drugs. Trends Parasitol 19 452 460
23. MolineauxL
GramicciaG
1980 The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. Geneva World Health Organization
24. HanET
LeeDH
ParkKD
SeokWS
KimYS
2006 Reemerging vivax malaria: Changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol 44 285 294
25. DolaSK
1974 Mass drug administration as a supplementary attack measure in malaria eradication programme. East Afr Med J 51 529 531
26. PinottiM
1954 A new method of malaria prophylaxis: The addition of an antimalarial drug to cooking salt used in daily preparation of food. Rev Brasil Malariol 6 5 12
27. PetersW
1970 Chemotherapy and drug resistance in malaria. London Academic Press
28. ClydeDF
1965 Duration of antimalarial activity of cycloguanil pamoate amond semi-immune Africans in Tanzania. WHO/MAL/506.65. Geneva World Health Organization
29. NoedlH
SeY
SchaecherK
SmithBL
2008 Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359 2619 2620
30. The malERA Consultative Group on Vaccines 2011 A research agenda for malaria eradication: Vaccines. PLoS Med e1000398 doi:10.1371/journal.pmed.1000398
31. PetersW
1957 A malaria survey in the Western District of Papua. P N G Med J 2 25 38
32. RuwendeC
KhooSC
SnowRW
YatesSN
KwiatkowskiD
1995 Natural selection of hemi - and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 376 246 249
33. CorteseJF
CaraballoA
ContrerasCE
2002 Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186 999 1006
34. WhiteNJ
OlliaroPL
1996 Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria. Parasitol Today 12 399 401
35. NyuntMM
HendrixCW
BakshiRP
KumarN
ShapiroTA
2009 Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg 80 528 535
36. DondorpAM
WhiteL
NguonC
DayNP
2010 Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8 272 280
37. The malERA Consultative Group on Modeling 2011 A research agenda for malaria eradication: Modeling. PLoS Med e1000403 doi:10.1371/journal.pmed.1000403
38. The malERA Consultative Group on Health Systems and Operational Research 2011 A research agenda for malaria eradication: Health systems and operational research. PLoS Med e1000397 doi:10.1371/journal.pmed.1000397
39. The malERA Consultative Group on Monitoring, Evaluation, and Surveillance 2011 A research agenda for malaria eradication: Monitoring, evaluation, and surveillance. PLoS Med e1000400 doi:10.1371/journal.pmed.1000400
40. The malERA Consultative Group on Integration Strategies 2011 A research agenda for malaria eradication: Cross-cutting issues for eradication. PLoS Med e1000404 doi:10.1371/journal.pmed.1000404
Zvýšte si kvalifikáciu online z pohodlia domova
Nemáte účet? Registrujte sa
Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.
